<DOC>
	<DOCNO>NCT01828554</DOCNO>
	<brief_summary>The purpose research study find happen capecitabine body dose use actual versus ideal body weight subject advance tumor elevate body mass index .</brief_summary>
	<brief_title>Capecitabine Pharmacokinetics ( PK ) -Actual Versus Ideal Body Weight</brief_title>
	<detailed_description>Cycle 1 : Capecitabine 1,250 mg/m2 PO BID 7 consecutive day ( D1 - D7 ) administer subject ( Ideal Body Weight use determine BSA ) dosage . Day 8-No drug administer . Capecitabine 1,250 mg/m2 PO BID 7 consecutive day ( D9 - D15 ) administer subject ( Actual Body Weight use determine BSA ) dosage . There 6 consecutive day drug administer subject ( Days 16-21 ) . Cycle 2 beyond : Capecitabine 1,250 mg/m2 PO BID 14 consecutive day ( D1 - D14 ) administer subject ( Actual Body Weight use determine BSA ) dosage . Days 15-21-No drug administer .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced metastatic cancer capecitabine treatment consider standard treatment option . Patients measurable evaluable disease eligible Patient 's Body Mass Index must 30 kg/m2 high . Eastern Cooperative Oncology Group performance status 02 . Age &gt; 18 year . Life expectancy great 12 week . Patients must adequate organ marrow function define : Hematologic : Absolute Neutrophil Count ( ANC ) &gt; 1000/mcL ( microliters ) , Hemoglobin &gt; 8gm/dL ( transfusion permit ) platelet &gt; 75,000/mcL Renal : serum creatinine ≤ upper limit normal ( ULN ) creatinine clearance ( CrCl ) ( either estimate calculate ) &gt; 60 mL/min/1.73 patient creatinine level institutional normal . Females : Crcl = ( 140age ) ( weight kg ) ( 0.85 ) /72 x Serum creatinine Males : Crcl = ( 140age ) ( weight kg ) /72 x Serum creatinine Hepatic : Serum Bilirubin ≤ 1.5x ULN No liver metastasis : Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) ≤ 2.5x ULN Liver metastases : AST ALT ≤ 5x ULN Ability understand willingness sign write informed consent document . Capecitabine contraindicate pregnant woman know detrimental effect fetus . A negative pregnancy test require premenopausal woman within 14 day study therapy initiation . Women childbearing potential men active female sexual partner must agree use adequate contraception ( hormonal , surgical , barrier method abstinence allow ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients systemic chemotherapy target therapy within 3 week radiotherapy within 2 week prior enter study patient whose adverse event prior therapy recover &lt; grade 1 still consider clinically significant . Patients receive investigational agent cancer treatment . Patients treat , stable brain metastasis allow enroll . Patients must least 4 week brain radiation medication use treat brain metastasis include steroid . Patients allow antiepileptic medication contraindicate base druginteraction table . Patients condition gastrointestinal tract expect result inability swallow absorb oral medication ( ie . prior surgical procedure affect absorption require i.v . alimentation ) . This determined discretion PI . Patients may take concomitant drug contraindicate base druginteraction table . Concurrent treatment warfarin ( coumadin ) allow , close monitoring PT/INR ( Prothrombin Time/International Normalized Ratio ) recommend . Uncontrolled intercurrent illness include , limited , ongoing active severe infection , symptomatic congestive heart failure , unstable angina pectoris , clinically significant symptomatic cardiac arrhythmia , malignancy require therapy psychiatric illness/social situation would limit compliance study requirement . Pregnant woman woman breastfeed exclude study capecitabine pregnancy category D drug know pas infant breastmilk . Patients known deficiency dihydropyrimidine dehydrogenase ( DPD ) enzyme . History allergic reaction attribute compound similar chemical biologic composition capecitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Capecitabine pharmacokinetics PK</keyword>
	<keyword>Elevated Body Mass Index ( BMI )</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>